HematologyUniversity of Washington Medical CenterSeattle, Washington, United States
OC 65.1 - Long-Term Efficacy and Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Immune Thrombocytopenia
Tuesday, June 27, 202314:45 – 15:00 ET
